Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPY4R | P50391 | 16/20 | 0.55 |
| ▸ | NPY1R | P25929 | 9/20 | 0.55 |
| ▸ | NPY2R | P49146 | 7/20 | 0.55 |
| ▸ | NPY5R | Q15761 | 6/20 | 0.55 |
| ▸ | FURIN | P09958 | 1/20 | 0.44 |
| ▸ | PCSK6 | P29122 | 1/20 | 0.44 |
| ▸ | BACE1 | P56817 | 2/20 | 0.41 |
| ▸ | CTSD | P07339 | 1/20 | 0.41 |
| ▸ | TFPI | P10646 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3459806 | 1.00 | NPY4R (0.55) | NPY4RNPY1RNPY2RNPY5RFURIN | |
| SCHEMBL30881172 | 1.00 | NPY4R (0.55) | NPY4RNPY1RNPY2RNPY5RFURIN | |
| SCHEMBL30486089 | 0.94 | NPY4R (0.49) | NPY4RNPY1RNPY2RNPY5RFURIN | |
| SCHEMBL30903441 | 0.94 | NPY4R (0.60) | NPY4RNPY1RNPY2RNPY5R | |
| SCHEMBL30486088 | 0.94 | NPY4R (0.46) | NPY4RNPY1RNPY2RNPY5RFURIN | |
| SCHEMBL30068491 | 0.94 | NPY4R (0.53) | NPY4RNPY1RNPY2RNPY5RBACE1 | |
| SCHEMBL31665975 | 0.94 | NPY4R (0.51) | NPY4RNPY1RNPY2RNPY5RFURIN | |
| SCHEMBL31643184 | 0.93 | NPY4R (0.54) | NPY4RNPY1RNPY2RNPY5R | |
| SCHEMBL30490411 | 0.93 | NPY4R (0.62) | NPY4RNPY1RNPY2RNPY5R | |
| SCHEMBL29872588 | 0.93 | NPY4R (0.62) | NPY4RNPY1RNPY2RNPY5R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-102370985-A | Purpose of agonist of natriuretic peptide receptor A in pain management | SHANGHAI INST BIOL SCIENCES | 2012-03-14 | — | — | CN | disclosed |
| US-20100216714-A1 | NATRIURETIC COMPOUNDS, CONJUGATES, AND USES THEREOF | JAMES KENNETH D | 2010-08-26 | — | — | US | disclosed |
| EP-1569683-B1 | MODIFIED NATRIURETIC COMPOUNDS, CONJUGATES, AND USES THEREOF | BIOCON LTD (IN) | 2010-03-03 | — | — | EP | disclosed |
| US-7648962-B2 | which retain activity for stimulating cyclic guanosine monophosphate production and binding to natriuretic peptide receptor type A; improved bioavailability and half-life in circulation; for treatment of congestive heart failure | BIOCON LIMITED (IN) | 2010-01-19 | — | — | US | disclosed |
| CN-100558398-C | Modified natriuretic compounds, conjugates, and uses thereof | NOBEX CORP (IN) | 2009-11-11 | — | — | CN | disclosed |
| US-20080207505-A1 | Bna Conjugates and Methods of Use | JAMES KENNETH D | 2008-08-28 | — | — | US | disclosed |
| CN-101027073-A | Natriuretic compounds, conjugates, and uses thereof | BIOCON LTD (IN) | 2007-08-29 | — | — | CN | disclosed |
| US-20060172933-A1 | Natriuretic compounds, conjugates, and uses thereof | BIOCON LIMITED (IN) | 2006-08-03 | — | — | US | disclosed |
| WO-2006076471-A2 | BNP CONJUGATES AND METHODS OF USE | NOBEX CORPORATION (US) | 2006-07-20 | — | — | WO | disclosed |
| US-20060074009-A1 | Natriuretic compounds, conjugates, and uses thereof | BIOCON LIMITED (IN) | 2006-04-06 | — | — | US | disclosed |
| CN-1741814-A | Modified naturetic compounds, conjugates, and uses thereof | NOBEX CORP (US) | 2006-03-01 | — | — | CN | disclosed |
| US-6028055-A | USE IN TREATMENT OR PROPHYLAXIS OF VARIOUS PATHOLOGICAL CONDITIONS ASSOCIATED WITH WATER OR ELECTROLYTE IMBALANCE | GENETECH, INC. (US) | 2000-02-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080207505-A1 | Bna Conjugates and Methods of Use | NPR1, NPPA, NPR3 | NPY4R 75/4885NPY1R 30/4885NPY2R 33/4885 |
| US-20100216714-A1 | NATRIURETIC COMPOUNDS, CONJUGATES, AND USES THEREOF | NPR1, NPPA, NPR3 | NPY4R 64/4885NPY1R 28/4885NPY2R 38/4885 |
| US-20060074009-A1 | Natriuretic compounds, conjugates, and uses thereof | NPR1, NPPA, NPR3 | NPY4R 64/4885NPY1R 28/4885NPY2R 38/4885 |
| US-20060172933-A1 | Natriuretic compounds, conjugates, and uses thereof | NPR1, NPPA, NPR3 | NPY4R 64/4885NPY1R 28/4885NPY2R 38/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.